Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?

Stefan Glck, Adrian Yun San Yip, Elizabeth Lam Yan Ng

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In recent years, molecular research has translated into remarkable changes for breast cancer diagnostics and therapeutics. Molecular tests such as Oncotype DX® and MammaPrint® have revolutionized the predictive and prognostic tools in the clinic. By stratifying the risk of recurrence for patients, the tests are able to provide clinicians with more information on the treatment outcomes of using chemotherapy, endocrine therapy or combination therapies for patients with genetic expression patterns. However, it is still questionable for clinical applications as some areas remain unclear; the true benefit still needs prospective evaluation. In this paper, the limitation and the possibility to replace traditional histopathologic features of molecular tests are discussed. At the moment, it seems there are still limitations that prevent microarrays from replacing the microscope for diagnosis, prognosis and treatment of early breast cancer. However, additional important clinical information is added to traditional histology and IHC determination of ER, PR and HER2 in terms of prognostic and predictive power.

Original languageEnglish
JournalExpert Opinion on Therapeutic Targets
Volume16
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 1 2012
Externally publishedYes

Fingerprint

Histology
Chemotherapy
Microarrays
Microscopes
Breast Neoplasms
Therapeutics
Recurrence
Drug Therapy
Research

Keywords

  • Early breast cancer
  • Microarrays
  • Microscope
  • Molecular tests

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer? / Glck, Stefan; Yip, Adrian Yun San; Ng, Elizabeth Lam Yan.

In: Expert Opinion on Therapeutic Targets, Vol. 16, No. SUPPL. 1, 01.03.2012.

Research output: Contribution to journalArticle

Glck, Stefan ; Yip, Adrian Yun San ; Ng, Elizabeth Lam Yan. / Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?. In: Expert Opinion on Therapeutic Targets. 2012 ; Vol. 16, No. SUPPL. 1.
@article{41d7045da49a4c1a88af86b61fd2c2c3,
title = "Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?",
abstract = "In recent years, molecular research has translated into remarkable changes for breast cancer diagnostics and therapeutics. Molecular tests such as Oncotype DX{\circledR} and MammaPrint{\circledR} have revolutionized the predictive and prognostic tools in the clinic. By stratifying the risk of recurrence for patients, the tests are able to provide clinicians with more information on the treatment outcomes of using chemotherapy, endocrine therapy or combination therapies for patients with genetic expression patterns. However, it is still questionable for clinical applications as some areas remain unclear; the true benefit still needs prospective evaluation. In this paper, the limitation and the possibility to replace traditional histopathologic features of molecular tests are discussed. At the moment, it seems there are still limitations that prevent microarrays from replacing the microscope for diagnosis, prognosis and treatment of early breast cancer. However, additional important clinical information is added to traditional histology and IHC determination of ER, PR and HER2 in terms of prognostic and predictive power.",
keywords = "Early breast cancer, Microarrays, Microscope, Molecular tests",
author = "Stefan Glck and Yip, {Adrian Yun San} and Ng, {Elizabeth Lam Yan}",
year = "2012",
month = "3",
day = "1",
doi = "10.1517/14728222.2012.655725",
language = "English",
volume = "16",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?

AU - Glck, Stefan

AU - Yip, Adrian Yun San

AU - Ng, Elizabeth Lam Yan

PY - 2012/3/1

Y1 - 2012/3/1

N2 - In recent years, molecular research has translated into remarkable changes for breast cancer diagnostics and therapeutics. Molecular tests such as Oncotype DX® and MammaPrint® have revolutionized the predictive and prognostic tools in the clinic. By stratifying the risk of recurrence for patients, the tests are able to provide clinicians with more information on the treatment outcomes of using chemotherapy, endocrine therapy or combination therapies for patients with genetic expression patterns. However, it is still questionable for clinical applications as some areas remain unclear; the true benefit still needs prospective evaluation. In this paper, the limitation and the possibility to replace traditional histopathologic features of molecular tests are discussed. At the moment, it seems there are still limitations that prevent microarrays from replacing the microscope for diagnosis, prognosis and treatment of early breast cancer. However, additional important clinical information is added to traditional histology and IHC determination of ER, PR and HER2 in terms of prognostic and predictive power.

AB - In recent years, molecular research has translated into remarkable changes for breast cancer diagnostics and therapeutics. Molecular tests such as Oncotype DX® and MammaPrint® have revolutionized the predictive and prognostic tools in the clinic. By stratifying the risk of recurrence for patients, the tests are able to provide clinicians with more information on the treatment outcomes of using chemotherapy, endocrine therapy or combination therapies for patients with genetic expression patterns. However, it is still questionable for clinical applications as some areas remain unclear; the true benefit still needs prospective evaluation. In this paper, the limitation and the possibility to replace traditional histopathologic features of molecular tests are discussed. At the moment, it seems there are still limitations that prevent microarrays from replacing the microscope for diagnosis, prognosis and treatment of early breast cancer. However, additional important clinical information is added to traditional histology and IHC determination of ER, PR and HER2 in terms of prognostic and predictive power.

KW - Early breast cancer

KW - Microarrays

KW - Microscope

KW - Molecular tests

UR - http://www.scopus.com/inward/record.url?scp=84857560540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857560540&partnerID=8YFLogxK

U2 - 10.1517/14728222.2012.655725

DO - 10.1517/14728222.2012.655725

M3 - Article

C2 - 22316427

AN - SCOPUS:84857560540

VL - 16

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - SUPPL. 1

ER -